More than 20 million Americans are currently affected by cataracts, and a new survey from AARP Media Sales and Alcon, the global leader in eye care, found that there are many questions and misperceptions among baby boomers about the condition, their options and how to treat it.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63529-alcon-and-a-a-r-p-mark-world-sight-day-first-live-cataract-education-event
WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, announced today its new WebMD Allergy app for the iPhone, an innovative new mobile resource that empowers consumers to take control of their allergies. It is the first free app to provide allergy sufferers with personalized location-based allergy condition forecasts in combination with WebMD’s trusted information and insights. WebMD Allergy is further personalized with optional mobile push notifications that warn when allergen levels are high, enabling app users to proactively manage their allergy conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60044-webmd-introduces-new-allergy-app-for-iphone
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
There is only one choice when it come to nutrition that slows down kidney disease and helps joint problems at the same time - The Hill's Science Diet K/D + Mobility.
Learn more here: https://tier1petproducts.com/best-dog-food-for-kidney-disease/
Chronic kidney disease (CKD) is a condition often associated with advanced age. According to recent data 1 out of 10 dogs will develop CKD in his lifetime.
It is also common for senior dogs to develop other age-related conditions such as reduced mobility or cognitive dysfunction which can significantly impact the quality of life of both the pet and the pet parent.
Nutrition can play a key role in managing these age-related conditions. That is why Hill’s nutritionists and veterinarians developed new Prescription Diet K/D + Mobility for dogs.
www.26northyachts.com
This Horizon 105 motoryacht features a 5 stateroom layout with on-deck master and huge fly-bridge for entertaining. Recently serviced twin MTU 16V2000 only have 900 hours making this motoryacht the best Horizon 105 on the market. Evan Marshall designed interior shows in excellent condition with marble floors, spacious main salon with a fully stocked bar and dining table for 10.
This Horizon 105 offers large aft deck, two garages for jet skis, walk-around decks, large fly-bridge, on-deck master, stabilizers, bow and stern thrusters, low hour MTU's and an immaculate interior that you will be proud to show.
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Asia-Pacific
Dr. Jeong Chan-woo from South Korea
Sharing skin love - Skin Health Promotion for Orphanage and for low-income children/youth
This initiative was established to help children from low-income families, without parents or those living away from their parents, to receive education on how to prevent skin diseases. They also have access to high quality treatment if they are suffering from a dermatological condition.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For North America
Dr. Danielle Marcoux from Canada
Camp Liberté – Summer camp for children with skin disorders
This one-week summer camp run by volunteer dermatologists and nurses enrolled children aged 7 to 12 with moderate-to-severe skin disorders, as well as their families, to bring them together for support, social interaction and to increase their confidence. All the activities aim to increase patients’ confidence and self-esteem, improve social skills, reduce stigma about their condition and improve adherence to treatment.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Africa and Arab States
Prof. Khalid Mohammed AlGhamdi from Saudi Arabia
Charity Society known as Faal to empower and support vitiligo patients in Saudi Arabia
Vitiligo is a long-term skin condition that causes pale, white patches on the skin due to a lack of melanin. This project aimed to increase awareness via TV broadcasts, schools visits and to provide psychological and social support to patients with vitiligo through training courses and different education programs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
This Oceanfast 123’ motoryacht carries 4 staterooms with an on-deck master. Having undergone a major refit in 2012 including a complete paint job she shows in excellent condition and ready to go cruising. Powered by twin MTU 8V396 TE94 with the W5's completed in 2012. Perseverance II offers the interior volume and exterior space comparable to much larger yachts. Niad stabilizers, KVH V-Sat television, on-deck master, sky-lounge, tender garage and spacious sun-deck, Perseverance II stands alone in her class. Under the present ownership, she has spent a considerable amount of time cruising the East Coast, Caribbean and Great Lakes.
The latest lash breakthrough is here. From Rimmel, you can get the Moroccan Argan oil your hair loves in a Rimmel mascara with new Wonder’lash Mascara with Argan Oil. Condition lashes and break through clumps for full, smooth volume. The unique brush’s super-soft bristles hug and coat each lash, perfectly separating them from root to tip. Even small corner lashes are dramatically transformed for an effortlessly eye-catching look. Lashes are left smoother, sleeker, and more defined than ever.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7428651-rimmel-london-wonder-lash/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
